Therapeutic Effect of Topical Gamma-Linolenic Acid on Refractory Uremic Pruritus

Yung Chih Chen, Wan Ting Chiu, Mai Szu Wu

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Pruritus is a bothersome symptom affecting up to 80% of dialysis patients. Lymphocyte and cytokine interaction has an important role in the pathogenesis of uremic pruritus. Gamma-linolenic acid (GLA) is associated with immune modulation of T lymphocytes and lymphokines. The aim of this study is to determine whether topical GLA can attenuate uremic pruritus. Methods: Seventeen dialysis patients with refractory uremic pruritus who passed the screening criteria entered a prospective, randomized, double-blind, placebo-controlled, crossover study. They stopped all antipruritic therapy at least 2 weeks before the study and were randomly assigned to treatment with either GLA 2.2% cream or placebo-based cream applied to the entire body after taking a bath once a day and to pruritic sites 3 times a day for 2 weeks, and then the reverse treatment after a 2-week washout period. Severity of pruritus was evaluated by using a traditional visual analogue scale (VAS) and a modified questionnaire method (pruritus score [PS]). Hemogram, aspartate and alanine aminotransferases, bilirubin, albumin, blood urea nitrogen, creatinine, calcium, phosphate, and intact parathyroid hormone were measured. Results: Sixteen patients completed the study; 1 patient was withdrawn because of an allergic skin reaction. There were no significant differences between groups except for sex distribution. Median VAS and PS values between groups did not differ significantly at baseline. There is a greater antipruritic effect of GLA based on evaluation with both the VAS and PS. There is persistence of a residual effect into the second treatment period after GLA treatment. Conclusion: GLA-rich cream is better than placebo-based cream for alleviating uremic pruritus. It is a useful adjuvant in the management of refractory uremic pruritus.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume48
Issue number1
DOIs
Publication statusPublished - Jul 2006
Externally publishedYes

Fingerprint

gamma-Linolenic Acid
Therapeutic Uses
Pruritus
Antipruritics
Visual Analog Scale
Placebos
Dialysis
Therapeutics
Sex Distribution
Lymphokines
Blood Urea Nitrogen
Aspartate Aminotransferases
Parathyroid Hormone
Alanine Transaminase
Baths
Bilirubin
Cross-Over Studies
Albumins
Creatinine
Hypersensitivity

Keywords

  • Gamma-linolenic acid
  • uremic pruritus

ASJC Scopus subject areas

  • Nephrology

Cite this

Therapeutic Effect of Topical Gamma-Linolenic Acid on Refractory Uremic Pruritus. / Chen, Yung Chih; Chiu, Wan Ting; Wu, Mai Szu.

In: American Journal of Kidney Diseases, Vol. 48, No. 1, 07.2006, p. 69-76.

Research output: Contribution to journalArticle

@article{8fb35aa9ed4342e3a5b3b31f515bc7e7,
title = "Therapeutic Effect of Topical Gamma-Linolenic Acid on Refractory Uremic Pruritus",
abstract = "Background: Pruritus is a bothersome symptom affecting up to 80{\%} of dialysis patients. Lymphocyte and cytokine interaction has an important role in the pathogenesis of uremic pruritus. Gamma-linolenic acid (GLA) is associated with immune modulation of T lymphocytes and lymphokines. The aim of this study is to determine whether topical GLA can attenuate uremic pruritus. Methods: Seventeen dialysis patients with refractory uremic pruritus who passed the screening criteria entered a prospective, randomized, double-blind, placebo-controlled, crossover study. They stopped all antipruritic therapy at least 2 weeks before the study and were randomly assigned to treatment with either GLA 2.2{\%} cream or placebo-based cream applied to the entire body after taking a bath once a day and to pruritic sites 3 times a day for 2 weeks, and then the reverse treatment after a 2-week washout period. Severity of pruritus was evaluated by using a traditional visual analogue scale (VAS) and a modified questionnaire method (pruritus score [PS]). Hemogram, aspartate and alanine aminotransferases, bilirubin, albumin, blood urea nitrogen, creatinine, calcium, phosphate, and intact parathyroid hormone were measured. Results: Sixteen patients completed the study; 1 patient was withdrawn because of an allergic skin reaction. There were no significant differences between groups except for sex distribution. Median VAS and PS values between groups did not differ significantly at baseline. There is a greater antipruritic effect of GLA based on evaluation with both the VAS and PS. There is persistence of a residual effect into the second treatment period after GLA treatment. Conclusion: GLA-rich cream is better than placebo-based cream for alleviating uremic pruritus. It is a useful adjuvant in the management of refractory uremic pruritus.",
keywords = "Gamma-linolenic acid, uremic pruritus",
author = "Chen, {Yung Chih} and Chiu, {Wan Ting} and Wu, {Mai Szu}",
year = "2006",
month = "7",
doi = "10.1053/j.ajkd.2006.03.082",
language = "English",
volume = "48",
pages = "69--76",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Therapeutic Effect of Topical Gamma-Linolenic Acid on Refractory Uremic Pruritus

AU - Chen, Yung Chih

AU - Chiu, Wan Ting

AU - Wu, Mai Szu

PY - 2006/7

Y1 - 2006/7

N2 - Background: Pruritus is a bothersome symptom affecting up to 80% of dialysis patients. Lymphocyte and cytokine interaction has an important role in the pathogenesis of uremic pruritus. Gamma-linolenic acid (GLA) is associated with immune modulation of T lymphocytes and lymphokines. The aim of this study is to determine whether topical GLA can attenuate uremic pruritus. Methods: Seventeen dialysis patients with refractory uremic pruritus who passed the screening criteria entered a prospective, randomized, double-blind, placebo-controlled, crossover study. They stopped all antipruritic therapy at least 2 weeks before the study and were randomly assigned to treatment with either GLA 2.2% cream or placebo-based cream applied to the entire body after taking a bath once a day and to pruritic sites 3 times a day for 2 weeks, and then the reverse treatment after a 2-week washout period. Severity of pruritus was evaluated by using a traditional visual analogue scale (VAS) and a modified questionnaire method (pruritus score [PS]). Hemogram, aspartate and alanine aminotransferases, bilirubin, albumin, blood urea nitrogen, creatinine, calcium, phosphate, and intact parathyroid hormone were measured. Results: Sixteen patients completed the study; 1 patient was withdrawn because of an allergic skin reaction. There were no significant differences between groups except for sex distribution. Median VAS and PS values between groups did not differ significantly at baseline. There is a greater antipruritic effect of GLA based on evaluation with both the VAS and PS. There is persistence of a residual effect into the second treatment period after GLA treatment. Conclusion: GLA-rich cream is better than placebo-based cream for alleviating uremic pruritus. It is a useful adjuvant in the management of refractory uremic pruritus.

AB - Background: Pruritus is a bothersome symptom affecting up to 80% of dialysis patients. Lymphocyte and cytokine interaction has an important role in the pathogenesis of uremic pruritus. Gamma-linolenic acid (GLA) is associated with immune modulation of T lymphocytes and lymphokines. The aim of this study is to determine whether topical GLA can attenuate uremic pruritus. Methods: Seventeen dialysis patients with refractory uremic pruritus who passed the screening criteria entered a prospective, randomized, double-blind, placebo-controlled, crossover study. They stopped all antipruritic therapy at least 2 weeks before the study and were randomly assigned to treatment with either GLA 2.2% cream or placebo-based cream applied to the entire body after taking a bath once a day and to pruritic sites 3 times a day for 2 weeks, and then the reverse treatment after a 2-week washout period. Severity of pruritus was evaluated by using a traditional visual analogue scale (VAS) and a modified questionnaire method (pruritus score [PS]). Hemogram, aspartate and alanine aminotransferases, bilirubin, albumin, blood urea nitrogen, creatinine, calcium, phosphate, and intact parathyroid hormone were measured. Results: Sixteen patients completed the study; 1 patient was withdrawn because of an allergic skin reaction. There were no significant differences between groups except for sex distribution. Median VAS and PS values between groups did not differ significantly at baseline. There is a greater antipruritic effect of GLA based on evaluation with both the VAS and PS. There is persistence of a residual effect into the second treatment period after GLA treatment. Conclusion: GLA-rich cream is better than placebo-based cream for alleviating uremic pruritus. It is a useful adjuvant in the management of refractory uremic pruritus.

KW - Gamma-linolenic acid

KW - uremic pruritus

UR - http://www.scopus.com/inward/record.url?scp=33745210805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745210805&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2006.03.082

DO - 10.1053/j.ajkd.2006.03.082

M3 - Article

VL - 48

SP - 69

EP - 76

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -